Recently Food and Drug Administration, U. S. approved cobimetinib , a kinase inhibitor, for the treatment of metastatic melanoma. This drug is to be used as a combinational therapy along with vemurafenib. Cobimetinib is specifically indicated for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, in combination with vemurafenib.
Cobimetinib is supplied as a tablet for oral administration. The recommended dose is 60 mg (three 20 mg tablets) orally taken once daily with or without food for the first 21 days of each 28-day cycle until disease progression or unacceptable toxicity. If a dose is missed or if vomiting occurs when the dose is taken, resume dosing with the next scheduled dose. FDA Approval The FDA approval of cobimetinib was based on a randomized clinical study of 495 patients with previously untreated, BRAF V600…
